Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30027909 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL4059781 | 0.89 | L3MBTL1 (0.55) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL1554320 | 0.86 | KDM4E (0.53) | TSHRMAPTL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL6554270 | 0.85 | KDM4E (0.44) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL28448312 | 0.85 | KDM4E (0.44) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL2090857 | 0.85 | KDM4E (0.44) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL10903457 | 0.85 | L3MBTL1 (0.52) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL27283396 | 0.85 | L3MBTL1 (0.52) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL28118170 | 0.84 | ATM (0.58) | MEN1KMT2ATSHRMAPTTAAR1 | |
| SCHEMBL4646605 | 0.84 | KDM4E (0.47) | MEN1KMT2ATSHRMAPTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096425-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-108929226-A | A method of preparing benzoyl formic acid ester derivant | 广东工业大学 | 2018-12-04 | — | — | CN | claimed |
| CN-108440299-A | A method of preparing 4- nitro benzophenone class compounds | 长沙理工大学 | 2018-08-24 | — | — | CN | claimed |
| WO-2025122979-A1 | COMPOUNDS FOR SEROTONIN RECEPTOR ACTIVATION AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | ATAI THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240368151-A1 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024091506-A2 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117945973-A | Trifluoromethyl sulfoxide reagent and preparation method and application thereof | 西北大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117677618-A | Novel ergoline and method for treating mood disorders | 吉尔伽美什制药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-5172704-A | SMOKING COMPOSITIONS CONTAINING A VANILLIN-RELEASE ADDITIVE | PHILIP MORRIS INCORPORATED (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0510817-A1 | Smoking compositions containing a vanillin-release additive | Philip Morris Products Inc. (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5063225-A | Antiarrhythmia | ROUSSEL UCLAF (FR) | 1991-11-05 | — | — | US | disclosed |
| CN-1045777-A | Alpha-substitution-preparation method of 4-(quinoline-2-base-methoxyl group) toluylic acid and ester | BAYER AG (DE) | 1990-10-03 | — | — | CN | disclosed |
| EP-0150166-B1 | NOVEL ARYLACITIC ACID DERIVATIVES | PHARMACIA AB (SE) | 1988-07-20 | — | — | EP | disclosed |
| US-4695648-A | PROSTAGLANDIN DEHYDROGENASE INHIBITORS | PHARMACIA AB (SE) | 1987-09-22 | — | — | US | disclosed |
| EP-0168467-A1 | NOVEL ARYLACETIC ACID DERIVATIVES | PHARMACIA AB (SE) | 1986-01-22 | — | — | EP | disclosed |
| WO-1985003287-A1 | NOVEL ARYLACETIC ACID DERIVATIVES | PHARMACIA AB (SE) | 1985-08-01 | — | — | WO | disclosed |
| EP-0150166-A1 | Novel arylacitic acid derivatives | PHARMACIA AB (SE) | 1985-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TAAR1, TAAR5, NPY1R | MEN1 934/4885KMT2A 3544/4885TSHR 58/4885 |
| US-20240368151-A1 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | HTR2C, GRIN2C, ERG | MEN1 1273/4885KMT2A 346/4885TSHR 2356/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | MEN1 875/4885KMT2A 1502/4885TSHR 2208/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | MEN1 1844/4885KMT2A 217/4885TSHR 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.